scispace - formally typeset
Search or ask a question
Institution

University of Geneva

EducationGeneva, Switzerland
About: University of Geneva is a education organization based out in Geneva, Switzerland. It is known for research contribution in the topics: Population & Galaxy. The organization has 26887 authors who have published 65265 publications receiving 2931373 citations. The organization is also known as: Geneva University & Universite de Geneve.


Papers
More filters
Journal ArticleDOI
TL;DR: This work considers the possible mechanisms responsible for beta-cell death and impaired function and their relative contribution to insulin insufficiency in diabetes and proposes a unifying classification of diabetes.
Abstract: Increasing evidence indicates that decreased functional beta-cell mass is the hallmark of both Type 1 and Type 2 diabetes. This underlies the absolute or relative insulin insufficiency in both conditions. In this For Debate, we consider the possible mechanisms responsible for beta-cell death and impaired function and their relative contribution to insulin insufficiency in diabetes. Beta-cell apoptosis and impaired proliferation consequent to hyperglycaemia is one pathway that could be operating in all forms of diabetes. Autoimmunity and other routes to beta-cell death are also considered. Recognition of decreased functional beta-cell mass and its overlapping multifactorial aetiology in diabetic states, leads us to propose a unifying classification of diabetes.

411 citations

Journal ArticleDOI
Nabila Aghanim1, M. Ashdown2, J. Aumont1, Carlo Baccigalupi3  +215 moreInstitutions (56)
TL;DR: In this paper, the authors describe the identification, modelling, and removal of previously unexplained systematic effects in the polarization data of the Planck High Frequency Instrument (HFI) on large angular scales.
Abstract: This paper describes the identification, modelling, and removal of previously unexplained systematic effects in the polarization data of the Planck High Frequency Instrument (HFI) on large angular scales, including new mapmaking and calibration procedures, new and more complete end-to-end simulations, and a set of robust internal consistency checks on the resulting maps These maps, at 100, 143, 217, and 353 GHz, are early versions of those that will be released in final form later in 2016 The improvements allow us to determine the cosmic reionization optical depth τ using, for the first time, the low-multipole EE data from HFI, reducing significantly the central value and uncertainty, and hence the upper limit Two different likelihood procedures are used to constrain τ from two estimators of the CMB E- and B-mode angular power spectra at 100 and 143 GHz, after debiasing the spectra from a small remaining systematic contamination These all give fully consistent results A further consistency test is performed using cross-correlations derived from the Low Frequency Instrument maps of the Planck 2015 data release and the new HFI data For this purpose, end-to-end analyses of systematic effects from the two instruments are used to demonstrate the near independence of their dominant systematic error residuals The tightest result comes from the HFI-based τ posterior distribution using the maximum likelihood power spectrum estimator from EE data only, giving a value 0055 ± 0009 In a companion paper these results are discussed in the context of the best-fit PlanckΛCDM cosmological model and recent models of reionization

410 citations

Journal ArticleDOI
TL;DR: The results demonstrate the importance of NPY Y1 receptors in NPY-mediated cardiovascular response and in the regulation of body weight through central control of energy expenditure and are also indicative of a role for the Y1 receptor in the control of food intake.
Abstract: Neuropeptide Y (NPY) is a 36-amino-acid neurotransmitter which is widely distributed throughout the central and peripheral nervous system1. NPY involvement has been suggested in various physiological responses including cardiovascular homeostasis2 and the hypothalamic control of food intake3. At least six subtypes of NPY receptors have been described4,5. Because of the lack of selective antagonists, the specific role of each receptor subtype has been difficult to establish. Here we describe mice deficient for the expression of the Y1 receptor subtype. Homozygous mutant mice demonstrate a complete absence of blood pressure response to NPY, whereas they retain normal response to other vasoconstrictors. Daily food intake, as well as NPY-stimulated feeding, are only slightly diminished, whereas fast-induced refeeding is markedly reduced. Adult mice lacking the NPY Y1 receptor are characterized by increased body fat with no change in protein content. The higher energetic efficiency of mutant mice might result, in part, from the lower metabolic rate measured during the active period, associated with reduced locomotor activity. These results demonstrate the importance of NPY Y1 receptors in NPY-mediated cardiovascular response and in the regulation of body weight through central control of energy expenditure. In addition, these data are also indicative of a role for the Y1 receptor in the control of food intake.

410 citations

Journal ArticleDOI
TL;DR: Contrary to long-standing views, men and women with the APOE &egr;3/&egR;4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Abstract: Importance It is unclear whether female carriers of the apolipoprotein E (APOE) e4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources Twenty-seven independent research studies in the Global Alzheimer’s Association Interactive Network with data on nearly 58 000 participants. Study Selection Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE e3/e4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE e3/e4 had an increased risk of AD compared with men with APOE e3/e3. The APOE e2/e3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more ( P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE e3/e4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE e4/e4 showed increased risks vs individuals with e3/e4, but no significant differences between men and women with e4/e4 were seen. Conclusions and Relevance Contrary to long-standing views, men and women with the APOE e3/e4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.

410 citations

Journal ArticleDOI
TL;DR: The current knowledge on miRNA editing is discussed and how this mechanism regulates miRNA biogenesis and activity is discussed to deepen the knowledge of molecular mechanisms underlying complex diseases.
Abstract: MicroRNAs (miRNAs) are small non-coding RNAs with the capability of modulating gene expression at the post-transcriptional level either by inhibiting messenger RNA (mRNA) translation or by promoting mRNA degradation. The outcome of a myriad of physiological processes and pathologies, including cancer, cardiovascular and metabolic diseases, relies highly on miRNAs. However, deciphering the precise roles of specific miRNAs in these pathophysiological contexts is challenging due to the high levels of complexity of their actions. Indeed, regulation of mRNA expression by miRNAs is frequently cell/organ specific; highly dependent on the stress and metabolic status of the organism; and often poorly correlated with miRNA expression levels. Such biological features of miRNAs suggest that various regulatory mechanisms control not only their expression, but also their activity and/or bioavailability. Several mechanisms have been described to modulate miRNA action, including genetic polymorphisms, methylation of miRNA promoters, asymmetric miRNA strand selection, interactions with RNA-binding proteins (RBPs) or other coding/non-coding RNAs. Moreover, nucleotide modifications (A-to-I or C-to-U) within the miRNA sequences at different stages of their maturation are also critical for their functionality. This regulatory mechanism called “RNA editing” involves specific enzymes of the adenosine/cytidine deaminase family, which trigger single nucleotide changes in primary miRNAs. These nucleotide modifications greatly influence a miRNA’s stability, maturation and activity by changing its specificity towards target mRNAs. Understanding how editing events impact miRNA’s ability to regulate stress responses in cells and organs, or the development of specific pathologies, e.g., metabolic diseases or cancer, should not only deepen our knowledge of molecular mechanisms underlying complex diseases, but can also facilitate the design of new therapeutic approaches based on miRNA targeting. Herein, we will discuss the current knowledge on miRNA editing and how this mechanism regulates miRNA biogenesis and activity.

410 citations


Authors

Showing all 27203 results

NameH-indexPapersCitations
JoAnn E. Manson2701819258509
Joseph L. Goldstein207556149527
Kari Stefansson206794174819
David Baltimore203876162955
Mark I. McCarthy2001028187898
Michael S. Brown185422123723
Yang Gao1682047146301
Napoleone Ferrara167494140647
Marc Weber1672716153502
Alessandro Melchiorri151674116384
Andrew D. Hamilton1511334105439
David P. Strachan143472105256
Andrew Beretvas1411985110059
Rainer Wallny1411661105387
Josh Moss139101989255
Network Information
Related Institutions (5)
Max Planck Society
406.2K papers, 19.5M citations

93% related

University of Oxford
258.1K papers, 12.9M citations

93% related

University College London
210.6K papers, 9.8M citations

93% related

Centre national de la recherche scientifique
382.4K papers, 13.6M citations

93% related

Yale University
220.6K papers, 12.8M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023171
2022520
20214,280
20204,142
20193,581
20183,395